These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 38469242)

  • 21.
    Dong S; Li Y; Chen J; Li Y; Yang P; Li J
    Front Oncol; 2022; 12():1025930. PubMed ID: 36568229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Management of Patients with Recurrent and Metachronous Oligometastatic Prostate Cancer in the Era of PSMA PET.
    Sabbagh A; Mohamad O; Lichter KE; Hope TA
    Cancers (Basel); 2022 Dec; 14(24):. PubMed ID: 36551678
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oligometastatic Prostate Cancer: Current Status and Future Challenges.
    Jadvar H; Abreu AL; Ballas LK; Quinn DI
    J Nucl Med; 2022 Nov; 63(11):1628-1635. PubMed ID: 36319116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. UBE2S as a novel ubiquitinated regulator of p16 and β-catenin to promote bone metastasis of prostate cancer.
    Peng S; Chen X; Huang C; Yang C; Situ M; Zhou Q; Ling Y; Huang H; Huang M; Zhang Y; Cheng L; Zhang Q; Guo Z; Lai Y; Huang J
    Int J Biol Sci; 2022; 18(8):3528-3543. PubMed ID: 35637955
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The tumor volume after radical prostatectomy and its clinical impact on the prognosis of patients with localized prostate cancer.
    Yuk HD; Byun SS; Hong SK; Lee H
    Sci Rep; 2022 Apr; 12(1):6003. PubMed ID: 35397645
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prostate-specific membrane antigen-targeted theranostics: past, present, and future approaches.
    Hawkey NM; Sartor AO; Morris MJ; Armstrong AJ
    Clin Adv Hematol Oncol; 2022 Apr; 20(4):227-238. PubMed ID: 35389387
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [
    Evangelista L; Maurer T; van der Poel H; Alongi F; Kunikowska J; Laudicella R; Fanti S; Hofman MS
    Eur Urol Oncol; 2022 Jun; 5(3):273-282. PubMed ID: 35367165
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of a Novel Molecular Imaging Modality, Prostate-Specific Membrane Antigen Positron Emission Tomography, on the Management of Prostate Cancer.
    Patel NA; Reiter RE
    J Clin Oncol; 2022 May; 40(13):1497-1499. PubMed ID: 35201894
    [No Abstract]   [Full Text] [Related]  

  • 29.
    Wang Z; Zheng A; Li Y; Dong W; Liu X; Yuan W; Gao F; Duan X
    Front Oncol; 2021; 11():759053. PubMed ID: 34778079
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Current usage of stereotactic body radiotherapy for oligometastatic prostate cancer in Korea: patterns of care survey (KROG 19-08).
    Bae SH; Jang WI; Kang HC; Kim YI; Kim YH; Kim WC; Lee HK; Kim JH
    Ann Transl Med; 2021 Aug; 9(16):1291. PubMed ID: 34532428
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biomarkers in Prostate-Specific Membrane Antigen Theranostics.
    Vlachostergios PJ; Zachos I; Tzortzis V
    Diagnostics (Basel); 2021 Jun; 11(6):. PubMed ID: 34207069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical insignificance of [
    Arnfield EG; Thomas PA; Roberts MJ; Pelecanos AM; Ramsay SC; Lin CY; Latter MJ; Garcia PL; Pattison DA
    Eur J Nucl Med Mol Imaging; 2021 Dec; 48(13):4495-4507. PubMed ID: 34136957
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic Role of
    Awenat S; Piccardo A; Carvoeiras P; Signore G; Giovanella L; Prior JO; Treglia G
    Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33808825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Role of PSMA PET/CT imaging in the diagnosis, staging and restaging of prostate cancer.
    Bagguley D; Ong S; Buteau JP; Koschel S; Dhiantravan N; Hofman MS; Emmett L; Murphy DG; Lawrentschuk N
    Future Oncol; 2021 Jun; 17(17):2225-2241. PubMed ID: 33724868
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    Carlucci G; Ippisch R; Slavik R; Mishoe A; Blecha J; Zhu S
    J Nucl Med; 2021 Feb; 62(2):149-155. PubMed ID: 33443068
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genomic and phenotypic heterogeneity in prostate cancer.
    Haffner MC; Zwart W; Roudier MP; True LD; Nelson WG; Epstein JI; De Marzo AM; Nelson PS; Yegnasubramanian S
    Nat Rev Urol; 2021 Feb; 18(2):79-92. PubMed ID: 33328650
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and Survival Rates Associated With Ablative Stereotactic Radiotherapy for Patients With Oligometastatic Cancer: A Systematic Review and Meta-analysis.
    Lehrer EJ; Singh R; Wang M; Chinchilli VM; Trifiletti DM; Ost P; Siva S; Meng MB; Tchelebi L; Zaorsky NG
    JAMA Oncol; 2021 Jan; 7(1):92-106. PubMed ID: 33237270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlations of the
    Karyagar SS; Karyagar S; Guven O
    Hell J Nucl Med; 2020; 23(2):120-124. PubMed ID: 32716402
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic factors influencing overall survival in de novo oligometastatic prostate cancer patients.
    Rii J; Sakamoto S; Yamada Y; Takeshita N; Yamamoto S; Sazuka T; Imamura Y; Nakamura K; Komiya A; Komaru A; Fukasawa S; Nakatsu H; Akakura K; Ichikawa T
    Prostate; 2020 Aug; 80(11):850-858. PubMed ID: 32501559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sites of synchronous distant metastases and prognosis in prostate cancer patients with bone metastases at initial diagnosis: a population-based study of 16,643 patients.
    Zhao F; Wang J; Chen M; Chen D; Ye S; Li X; Chen X; Ren G; Yan S
    Clin Transl Med; 2019 Nov; 8(1):30. PubMed ID: 31784868
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.